VTYX - Ventyx stock plunges following Phase 2 results for ulcerative colitis drug
2023-10-09 17:01:06 ET
More on Ventyx Biosciences
- Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation
- Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Ventyx Biosciences
- Historical earnings data for Ventyx Biosciences
- Financial information for Ventyx Biosciences
For further details see:
Ventyx stock plunges following Phase 2 results for ulcerative colitis drug